Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 15/20 | 0.52 |
| ▸ | EZH1 | Q92800 | 7/20 | 0.52 |
| ▸ | EED | O75530 | 1/20 | 0.48 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.48 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.48 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.48 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17734418 | 0.94 | EZH2 (0.56) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL23863678 | 0.88 | EZH1 (0.64) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734416 | 0.85 | EZH2 (0.44) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL17734413 | 0.82 | EZH2 (0.71) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL24227152 | 0.81 | EZH2 (0.45) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL20621469 | 0.81 | EZH2 (0.71) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL2595575 | 0.77 | EZH2 (0.74) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734419 | 0.74 | EZH2 (0.45) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL23863738 | 0.74 | EZH2 (0.72) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL23863694 | 0.74 | EZH2 (0.57) | EZH2EZH1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885343-A1 | INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |